1.26 0.00 (0.00%)
After hours: 7:09PM EDT
|Bid||1.19 x 900|
|Ask||1.26 x 1100|
|Day's Range||1.17 - 1.26|
|52 Week Range||0.75 - 2.05|
|Beta (3Y Monthly)||4.01|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
MELBOURNE, Australia, Sept. 17, 2018-- Hainan Resort Software Community has on behalf of Hainan Ecological Smart City Group formally extended an invitation to Genetic Technologies Limited to establish ...
MELBOURNE, Australia, Aug. 21, 2018-- Representatives of the Hainan Government- Hainan Ecological Smart City Group, a Chinese industrial park development & operations company have formally invited Genetic ...
Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has signed a Heads of Agreement (Agreement) with Beijing Zishan Health Consultancy Limited (Zishan). Zishan will take on the functions of sales, account management, marketing and promotion of GTG’s genetic risk assessment products for the Chinese market.
Nasdaq: GENE, “Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a A$20 million Equity Placement Facility (the “Facility”) with the Kentgrove Capital Growth Fund (“Kentgrove Capital”), an investment fund managed by Kentgrove Capital Pty Ltd, a Melbourne-based investment management firm, to strengthen the Company’s funding position. Under the Facility, Kentgrove Capital may provide the Company with up to A$20 million of equity capital in a series of individual placements of up to $1 million (or a higher amount by mutual agreement) over the next 20 months.
Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a Framework Agreement (“Agreement”) with Blockchain Global Limited ACN 601 628 497 (“BCG”).
Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a non-exclusive distribution agreement with Swisstec Health Analytics Ltd. (“Swisstec”). This agreement grants Swisstec the right to explore opportunities to deliver GTG’s genetic screening tests to hospital networks in Asia.
NEW YORK, NY / ACCESSWIRE / July 17, 2018 / Genetic Technologies saw big gains on news that its breast cancer and colorectal cancer risk assessment tests are on track. Shares of Innovate were headed in the opposite direction on news that the company has filed a securities registration statement amendment with the SEC to issue up to $175 million of new stock and to sell 14 million shares of existing stock. Innovate Biopharmaceuticals, Inc.
Today, Genetic Technologies (GENE) was trading over 70% higher than yesterday’s closing price of $1.09. The stock jumped ~72.5% in premarket trading. The stock price and volumes rose on the news of the company’s on-track breast cancer and colorectal cancer risk assessment tests, slated for release in October.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Coda Octopus Group, Inc. (NASDAQ: CODA ) stock soared ...
Beyond 30,000, that’s where the Dow Jones Industrial Average (DJIA) is headed, according to Gene Simmons, known by many rock n’ roll fans as the KISS Demon. As of the close of trading on Tuesday, the Dow was sitting around 24,360, down 1.5% on the year. Since 1985, the Dow has gone through good times and bad, but has risen overall by nearly 1,800%.
TORONTO , March 20, 2018 /CNW/ - Dan Kriznic , Chairman, CEO, Founder & Director, alongside Gene Simmons , Co-Founder of KISS, and Chief Evangelist Officer, Invictus MD Strategies Corp. (GENE), joined ...
NASDAQ: GENE) to accelerate the prediction of cancer for millions of individuals worldwide. GTG, whose lead product is BREVAGenplus® - a clinically validated risk assessment test for non-hereditary breast cancer - is at the forefront of preventive medicine.